What Would A Biktarvy Slowdown Do To Gilead Stock?
For questions about this article or underlying research, email help@trefis.com. Gilead Sciences (GILD) stock has returned 31.6% over the past year, compared with a 15.1% return for the S&P 500, with HIV drugs led by Biktarvy still generating most of the company’s sales. During the August 4, 2026, call, management said growth in the HIV […]